-
-
-
Ki-Suck Jung
President, APSR 2022
Local Congress Committee
Professor, Hallym University College of Medicine -
Jae Jeong Shim
Secretary General, APSR 2022
Local Congress Committee
Professor, Korea University College of Medicine -
Jang-Won Sohn
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, Hanyang University College of Medicine -
Kwang Ha Yoo
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, Konkuk University School of Medicine -
Chin Kook Rhee
Vice Secretary General, APSR 2022
Local Congress Committee
Professor, The Catholic University of Korea College of Medicine
-
Speaker's Highlight
-
-
Don Sin
University of British Columbia, St. Paul Hospital (Canada)
Kenneth R. Chapman
Toronto General Hospital Research Institute (Canada)
-
Parameswaran Nair
McMaster University (Canada)
Carolyn Calfee
UCSF (U.S.A.)
-
Gregory P. Downey
University of Colorado School of Medicine (U.S.A.)
David A. Schwartz
University of Colorado School of Medicine (U.S.A.)
-
Neil Schluger
Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
Nick Kim
Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
-
Nicola Hananiah
Baylor College of Medicine (U.S.A.)
Jae-Joon Yim
Seoul National University College of Medicine (Republic of Korea)
-
Koichiro Asano
Tokai University School of Medicine (Japan)
Diahn-Warng Perng
Taipei Veterans General Hospital (Taiwan)
-
Konstantinos Kostikas
University of Ioannina (Greece)
Karin Klooster
University Medical Center Groningen (Kingdom of the Netherlands)
-
Pirfenidone in progressive fibrotic hypersensitivity pneumonitis
Progressive fibrotic hypersensitivity pneumonitis (PPF-HP) is persistent lung injury caused by an inhaled antigen, with worsening symptoms, declining function and fibrosis despite exposure control or anti-inflammatory treatment. Pirfenidone is considered as an adjunct in selected patients, not a replacement for removing the trigger.
At APSR 2022, organised in connection with APSR and KATRD, the discussion should focus on distinguishing PPF-HP from other progressive interstitial lung diseases and defining when antifibrotic therapy adds value. Australian teams also face a funding issue: pirfenidone has Therapeutic Goods Administration approval and Pharmaceutical Benefits Scheme subsidy for eligible idiopathic pulmonary fibrosis patients, while PPF-HP generally falls outside routine PBS coverage.
Why progressive fibrosis changes management
HP begins with immune-mediated inflammation after exposure to mould, animal proteins or chemicals. Chronic hypersensitivity pneumonitis with established fibrosis brings architectural distortion, restrictive physiology and a poorer outlook, particularly when imaging resembles usual interstitial pneumonia.
The sequence matters: identify and remove the antigen, treat clinically important inflammation, then consider antifibrotic therapy if decline persists. Combining these steps without a clear disease model can cause adverse effects while delaying potentially disease-modifying care.
Establishing the diagnosis and baseline
Diagnosis should come through a multidisciplinary ILD review, not high-resolution CT alone. Pulmonary function tests, oxygen assessment, exposure history and exclusion of infection, aspiration, drug toxicity and connective-tissue disease are considered together; bronchoscopy or biopsy is reserved for unresolved cases.
Patients may say "farmer's lung" or "bird fancier's lung" instead of hypersensitivity pneumonitis, so a structured occupational and domestic exposure history matters. Previous thoracic radiotherapy also deserves attention, because thoracic radiation history may reveal late oesophageal and pulmonary sequelae rather than a primary HP pattern.
Establish the baseline before treatment: serial forced vital capacity (FVC), diffusing capacity (DLCO), oxygen need, exercise tolerance and CT extent. Describe the phenotype as active, stable fibrotic or progressive, since that distinction influences whether immunosuppression, antifibrotic therapy or both are discussed.
What pirfenidone can contribute
Pirfenidone modulates TGF-beta and other fibrotic pathways. Its strongest evidence is in idiopathic pulmonary fibrosis, where it slows FVC decline and reduces progression events; that result cannot simply be transferred to PPF-HP.
HP data come mainly from small cohorts, retrospective series and selected cases. Signals of stabilised physiology are encouraging, but differences in antigen control, immunosuppression and fibrosis make the drug's independent effect hard to isolate. The evidence is promising, not definitive.
Pirfenidone is most logically considered when inflammation is controlled, antigen avoidance is incomplete or impossible, and serial assessment shows progression. It should not delay removing the cause, and it has not been shown to replace corticosteroids for active inflammatory HP.
Prescribing and monitoring in Australia
Australian prescribing starts with specialist review and informed consent for off-label use. The TGA-approved product information for IPF should guide dosing and monitoring, while current cost and PBS coverage must be checked because routine subsidy for PPF-HP is not available.
Before treatment, record:
- the suspected antigen and evidence that exposure has been reduced
- baseline FVC, DLCO, oxygen requirement and relevant CT findings
- liver tests, weight and review of concomitant medicines
- a measurable review interval, usually three to six months
During follow-up, review:
- liver enzymes and symptoms suggesting hepatic injury
- nausea, reflux, diarrhoea and adherence to prescribed doses
- spirometry performed with the same technique and equipment
- oxygen need, exercise capacity and any new exposure history
Many patients tolerate treatment, but gastrointestinal upset is common and significant liver injury can occur. Dose adjustment, closer liver testing or discontinuation may be required; an unexplained enzyme rise should not be ignored.
Access, exposure and equity
Access should fit Australia's geography and funding model. Public ILD services in Melbourne, Sydney, Brisbane, Adelaide and Perth use multidisciplinary reviews, while regional patients may use Medicare Benefits Schedule-supported telehealth alongside local spirometry; quality-controlled testing remains essential.
Occupational exposure is practical, not theoretical. Grain handling, poultry operations, bird keeping and mould after flooding can all be relevant in Australia. Ask specifically about silos, hay, birds, insulation and damp buildings, including changes in work, home or hobbies.
Medicare and public referrals support access, but an off-label medicine may require private payment, and specialist review can mean travel or fees. Explain that "bird fancier's lung" is a recognised lay term and that a written exposure-reduction plan is treatment, not an optional extra.
Comparing treatment strategies
Treatment decisions are easier when each option is matched to disease activity and local access. The evidence for IPF should be distinguished from the thinner, disease-specific evidence in PPF-HP.
No single approach settles the decision. A patient with active inflammation and an avoidable antigen may need a different sequence from one with stable scarring, and serial data may justify revisiting the plan.
Strategy Main role Evidence and limitations Australian considerations Pirfenidone Slows fibrotic progression Strong IPF evidence; limited PPF-HP cohorts Generally off-label for PPF-HP and outside routine PBS subsidy; monitor liver tests and gastrointestinal effects Nintedanib Oral antifibrotic alternative Evidence includes broader progressive fibrosing ILD populations, but HP-specific data remain limited Check current TGA approval and PBS criteria individually Corticosteroids with or without steroid-sparing drugs Controls active inflammation May help inflammatory disease but does not reverse established fibrosis Specialist-directed use requires infection, metabolic and blood monitoring Antigen avoidance, rehabilitation and oxygen Removes the trigger and supports function Core components of HP management May involve housing or workplace changes, allied-health referral and oxygen assessment A framework for the next review
A robust plan keeps three processes under review: the antigen, inflammation and fibrosis. Record each exposure or infection, each change in symptoms or oxygen needs, and the serial physiology used to decide whether the disease is progressing. A single CT scan or FVC measurement should not determine a long-term drug decision.
Shared decisions should address what a three-to-six-month trial can achieve. If function is stable and the antigen has been removed, continued observation may be preferable to immediate medication. If decline persists, document why progression is judged to be fibrotic rather than inflammatory, infection-related or treatment-related.
The immediate next step is for the treating respiratory physician to convene a multidisciplinary review, record the suspected antigen and serial lung-function trajectory, and confirm current PBS criteria before any off-label pirfenidone prescription.
Richard Russell
Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
-
Mona Bafadhel
King’s College London (United Kingdom)
David Jackson
Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
-
James Chalmers
University of Dundee (United Kingdom)
David Price
University of Aberdeen (United Kingdom)
-